Figure 1: DCs-based immunotherapeutic strategies: (1) to harvest peripheral blood mononuclear cells, (2) to generate immature DCs with cytokine stimulation, (3) to mature DCs by loading tumor antigens, (4) to transfer activated antigen-presenting DCs back to the patients, (5) to stimulate robust anti-tumor immune effector cells such as T cells and NK cells.